Last reviewed · How we verify
CarboP-pacliT
CarboP-pacliT is a chemotherapy medication that works by interfering with DNA replication in cancer cells.
CarboP-pacliT is a chemotherapy medication that works by interfering with DNA replication in cancer cells. Used for Non-small cell lung cancer.
At a glance
| Generic name | CarboP-pacliT |
|---|---|
| Also known as | Carboplatine, paclitaxel |
| Sponsor | Centre Oscar Lambret |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CarboP-pacliT is a platinum-based chemotherapy drug that forms platinum-DNA adducts, thereby inhibiting DNA replication and transcription in rapidly dividing cancer cells. This leads to cell death and ultimately, tumor shrinkage.
Approved indications
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |